• |
Net operating revenue was $163.3 million compared to $153.8 million in the first quarter of 2022 and $164.0 million in the second quarter of 2021, an increase of 6% quarter over quarter and essentially flat year over year.
|
■ |
Net patient revenue was $148.5 million compared to $138.9 million in the first quarter of 2022 and $146.7 million in the second quarter of 2021, an increase of 7% quarter over quarter and 1% year over year. See below for discussion of drivers to net patient revenue, i.e. patient visits and Rate per Visit.
|
■ |
Other revenue was $14.8 million compared to $14.9 million in the first quarter of 2022 and $17.4 million in the second quarter of 2021, a decrease of 1% quarter over quarter and 15% year over year. The year over year decrease was mostly due to sale of the Home Health service line on October 1, 2021.
|
• |
Visits per Day ("VPD") were 22,403 compared to 21,062 in the first quarter of 2022 and 21,569 in the second quarter of 2021, an increase of 6% quarter over quarter and 4% year over year.
|
• |
Rate per Visit was $103.57 compared to $103.06 in the first quarter of 2022 and $106.26 in the second quarter of 2021, essentially flat quarter over quarter and a decrease of 3% year over year. The year over year decrease was primarily due to the 2022 Medicare Physician Fee Schedule, which introduced a 0.75% decrease in overall rates and an additional 15% decrease in rates paid for services performed by physical therapy assistants, and unfavorable mix shifts in payors, states and services.
|
• |
Salaries and related costs were $89.6 million compared to $87.4 million in the first quarter of 2022 and $80.9 million in the second quarter of 2021, an increase of 3% quarter over quarter due to wage inflation and an increase of 11% year over year due to higher number of clinical FTE and wage inflation.
|
• |
Rent, clinic supplies, contract labor and other was $50.4 million compared to $51.6 million in the first quarter of 2022 and $44.1 million in the second quarter of 2021, a decrease of 2% quarter over quarter due to lower expenditures on a per clinic basis and an increase of 14% year over year due to more clinics and higher expenditures on a per clinic basis.
|
• |
Provision for doubtful accounts was $3.5 million compared to $3.6 million in the second quarter of 2021. PT provision as a percent of net patient revenue was 2% in both quarters.
|
• |
Selling, general and administrative expenses were $31.8 million compared to $30.0 million in the first quarter of 2022 and $26.4 million in the second quarter of 2021, an increase of 6% quarter over quarter primarily due to a probable legal settlement arising from a payor billing dispute, partially offset by lower debt refinancing fees, and an increase of 21% year over year due to the aforementioned legal settlement, higher public company operating costs and non-ordinary legal and regulatory costs, partially offset by lower transaction costs.
|
• |
Non-cash goodwill impairment charge was approximately $87.9 million, and the non-cash trade name indefinite-lived intangible asset impairment charge was approximately $40.0 million. Due to an increase in discount rate, driven by an increase in Treasury rates, and revised near-term Company expectations given current labor market headwinds it was determined that the fair value amounts of goodwill and trade name were below their respective carrying amounts.
|
• |
Income tax benefit was $13.0 million compared to $23.3 million in the first quarter of 2022 and $19.7 million in the second quarter of 2021.
|
• |
Net loss was $135.7 million compared to $138.2 million in the first quarter of 2022 and $439.1 million in the second quarter of 2021.
|
• |
Adjusted EBITDA1 was $5.4 million compared to $(4.7) million in the first quarter of 2022 and $24.0 million in the second quarter of 2021. Quarter over quarter, the increase was primarily driven by higher revenue, lower rent, clinic supplies, and contract labor costs and lower provision for doubtful accounts. Year over year, the decrease was primarily due to higher cost of services and higher selling, general, and administrative expenses as detailed above.
|
• |
Net increase (decrease) in cash was $31.1 million year-to-date 2022 compared to $(51.6) million in the first six months of 2021.
|
• |
Cash and cash equivalents totaled $79.7 million, and the revolving credit facility was undrawn with available capacity of $48.2 million, net of usage by letters of credit, equaling $127.9 million in available liquidity.
|
• |
Opened 10 new clinics in existing states, including Maryland and Pennsylvania; and 6 clinics were closed. This brings the total number of clinics to 926. The Company continues to capitalize on growth opportunities in individual markets, while optimizing its footprint and financial return in other local markets.
|
• |
Net Promotor Score ("NPS") of 75 and Google Star Rating of 4.9, reflecting continued high customer satisfaction and brand loyalty.
|
(i) |
changes in domestic business, market, financial, political and legal conditions, including shifts and trends in payor mix;
|
(ii) |
the ability to execute on our sales and marketing strategies;
|
(iii) |
the ability to maintain the listing of the Company's securities on NYSE;
|
(iv) |
risks related to the execution of ATI's business strategy, including but not limited to ramping of visits, growing clinical headcount, and opening new clinics, and the timing of expected business milestones;
|
(v) |
the effects of competition on ATI's future business and the ability of ATI to grow and manage growth profitably, maintain relationships with patients, payors and referral sources and retain its management and key employees;
|
(vi) |
the ability of the Company to attract and retain physical therapists consistent with its business plan;
|
(vii) |
the ability of the Company to develop new and retain and expand relationships with referral sources;
|
(viii) |
the outcome of any legal proceedings or regulatory investigations that have or may be instituted against the Company or any of its directors or officers and the availability of insurance coverage for such matters;
|
(ix) |
the ability of the company to comply with its covenants in its credit facility and preferred stock financing arrangements or to redeem preferred stock;
|
(x) |
the ability of the Company to issue equity or equity-linked securities or obtain debt financing in the future;
|
(xi) |
risks related to political and macroeconomic uncertainty, including recession, inflation, higher interest rates and the ongoing conflict between Russia and Ukraine;
|
(xii) |
the impact of the global COVID-19 pandemic (and existing or emerging variants) on any of the foregoing risks;
|
(xiii) |
risks related to the impact on our workforce of mandatory COVID-19 vaccination of employees;
|
(xiv) |
risks related to further impairments of goodwill and other intangible assets, which represent a significant portion of the Company's total assets, especially in view of the Company's recent market valuation;
|
(xv) |
risks associated with the Company's inability to remediate material weaknesses in internal controls over financial reporting related to income taxes and to maintain effective internal controls over financial reporting; and
|
Three Months Ended
|
Six Months Ended
| |||||||||||||||
June 30,
2022
|
June 30,
2021
|
June 30,
2022
|
June 30,
2021
| |||||||||||||
Net patient revenue
|
$
|
148,506
|
$
|
146,679
|
$
|
287,431
|
$
|
278,950
| ||||||||
Other revenue
|
14,787
|
17,354
|
29,684
|
34,145
| ||||||||||||
Net operating revenue
|
163,293
|
164,033
|
317,115
|
313,095
| ||||||||||||
Cost of services:
| ||||||||||||||||
Salaries and related costs
|
89,606
|
80,917
|
177,021
|
161,571
| ||||||||||||
Rent, clinic supplies, contract labor and other
|
50,405
|
44,079
|
102,020
|
87,375
| ||||||||||||
Provision for doubtful accounts
|
3,506
|
3,585
|
8,611
|
10,756
| ||||||||||||
Total cost of services
|
143,517
|
128,581
|
287,652
|
259,702
| ||||||||||||
Selling, general and administrative expenses
|
31,808
|
26,391
|
61,832
|
51,117
| ||||||||||||
Goodwill and intangible asset impairment charges
|
127,820
|
453,331
|
283,561
|
453,331
| ||||||||||||
Operating loss
|
(139,852
|
)
|
(444,270
|
)
|
(315,930
|
)
|
(451,055
|
)
| ||||||||
Change in fair value of warrant liability
|
(1,184
|
)
|
(4,539
|
)
|
(2,861
|
)
|
(4,539
|
)
| ||||||||
Change in fair value of contingent common shares liability
|
(1,496
|
)
|
(20,948
|
)
|
(25,830
|
)
|
(20,948
|
)
| ||||||||
Loss on settlement of redeemable preferred stock
|
-
|
14,037
|
-
|
14,037
| ||||||||||||
Interest expense, net
|
11,379
|
15,632
|
20,035
|
31,719
| ||||||||||||
Interest expense on redeemable preferred stock
|
-
|
4,779
|
-
|
10,087
| ||||||||||||
Other expense, net
|
205
|
5,626
|
2,986
|
5,779
| ||||||||||||
Loss before taxes
|
(148,756
|
)
|
(458,857
|
)
|
(310,260
|
)
|
(487,190
|
)
| ||||||||
Income tax benefit
|
(13,033
|
)
|
(19,731
|
)
|
(36,314
|
)
|
(30,246
|
)
| ||||||||
Net loss
|
(135,723
|
)
|
(439,126
|
)
|
(273,946
|
)
|
(456,944
|
)
|
June 30, 2022
|
December 31, 2021
| |||||||
Assets:
| ||||||||
Current assets:
| ||||||||
Cash and cash equivalents
|
$
|
79,680
|
$
|
48,616
| ||||
Accounts receivable (net of allowance for doubtful accounts of $47,809 and $53,533 at June 30, 2022 and December 31, 2021, respectively)
|
83,193
|
82,455
| ||||||
Prepaid expenses
|
14,663
|
9,303
| ||||||
Other current assets
|
13,013
|
3,204
| ||||||
Total current assets
|
190,549
|
143,578
| ||||||
Property and equipment, net
|
134,883
|
139,730
| ||||||
Operating lease right-of-use assets
|
245,886
|
256,646
| ||||||
Goodwill, net
|
404,374
|
608,811
| ||||||
Trade name and other intangible assets, net
|
331,951
|
411,696
| ||||||
Other non-current assets
|
2,013
|
2,233
| ||||||
Total assets
|
$
|
1,309,656
|
$
|
1,562,694
| ||||
Liabilities, Mezzanine Equity and Stockholders' Equity:
| ||||||||
Current liabilities:
| ||||||||
Accounts payable
|
$
|
14,369
|
$
|
15,146
| ||||
Accrued expenses and other liabilities
|
65,453
|
64,584
| ||||||
Current portion of operating lease liabilities
|
52,037
|
49,433
| ||||||
Current portion of long-term debt
|
-
|
8,167
| ||||||
Total current liabilities
|
131,859
|
137,330
| ||||||
Long-term debt, net
|
478,527
|
543,799
| ||||||
Warrant liability
|
1,480
|
4,341
| ||||||
Contingent common shares liability
|
19,530
|
45,360
| ||||||
Deferred income tax liabilities
|
31,145
|
67,459
| ||||||
Operating lease liabilities
|
237,821
|
250,597
| ||||||
Other non-current liabilities
|
1,935
|
2,301
| ||||||
Total liabilities
|
902,297
|
1,051,187
| ||||||
Commitments and contingencies
| ||||||||
Mezzanine equity:
| ||||||||
Series A Senior Preferred Stock, $0.0001 par value; 1.0 million shares authorized; $1,042.35 stated value per share and 0.2 million shares issued and outstanding at June 30, 2022; none issued and outstanding at December 31, 2021
|
140,340
|
-
| ||||||
Stockholders' equity:
| ||||||||
Class A common stock, $0.0001 par value; 470.0 million shares authorized; 207.2 million shares issued, 198.0 million shares outstanding at June 30, 2022; 207.4 million shares issued, 197.4 million shares outstanding at December 31, 2021
|
20
|
20
| ||||||
Treasury stock, at cost, 0.05 million shares and 0.03 million shares at June 30, 2022 and December 31, 2021, respectively
|
(129
|
)
|
(95
|
)
| ||||
Additional paid-in capital
|
1,375,241
|
1,351,597
| ||||||
Accumulated other comprehensive income
|
6,488
|
28
| ||||||
Accumulated deficit
|
(1,120,428
|
)
|
(847,132
|
)
| ||||
Total ATI Physical Therapy, Inc. equity
|
261,192
|
504,418
| ||||||
Non-controlling interests
|
5,827
|
7,089
| ||||||
Total stockholders' equity
|
267,019
|
511,507
| ||||||
Total liabilities, mezzanine equity and stockholders' equity
|
$
|
1,309,656
|
$
|
1,562,694
|
Six Months Ended
| ||||||||
June 30, 2022
|
June 30, 2021
| |||||||
Operating activities:
| ||||||||
Net loss
|
$
|
(273,946
|
)
|
$
|
(456,944
|
)
| ||
Adjustments to reconcile net loss to net cash used in operating activities:
| ||||||||
Goodwill and intangible asset impairment charges
|
283,561
|
453,331
| ||||||
Depreciation and amortization
|
20,369
|
18,768
| ||||||
Provision for doubtful accounts
|
8,611
|
10,756
| ||||||
Deferred income tax provision
|
(36,314
|
)
|
(30,246
|
)
| ||||
Amortization of right-of-use assets
|
24,071
|
22,349
| ||||||
Non-cash share-based compensation
|
3,919
|
3,616
| ||||||
Amortization of debt issuance costs and original issue discount
|
1,407
|
2,045
| ||||||
Non-cash interest expense on redeemable preferred stock
|
-
|
10,087
| ||||||
Loss on extinguishment of debt
|
2,809
|
5,534
| ||||||
Loss on settlement of redeemable preferred stock
|
-
|
14,037
| ||||||
(Gain) loss on disposal and impairment of assets
|
(163
|
)
|
472
| |||||
Change in fair value of warrant liability
|
(2,861
|
)
|
(4,539
|
)
| ||||
Change in fair value of contingent common shares liability
|
(25,830
|
)
|
(20,948
|
)
| ||||
Changes in:
| ||||||||
Accounts receivable, net
|
(9,349
|
)
|
(3,767
|
)
| ||||
Prepaid expenses and other current assets
|
(7,555
|
)
|
(1,621
|
)
| ||||
Other non-current assets
|
22
|
(199
|
)
| |||||
Accounts payable
|
1,850
|
1,943
| ||||||
Accrued expenses and other liabilities
|
10,803
|
(21,117
|
)
| |||||
Operating lease liabilities
|
(23,427
|
)
|
(27,563
|
)
| ||||
Other non-current liabilities
|
45
|
766
| ||||||
Medicare Accelerated and Advance Payment Program Funds
|
(10,759
|
)
|
(3,869
|
)
| ||||
Net cash used in operating activities
|
(32,737
|
)
|
(27,109
|
)
| ||||
Investing activities:
| ||||||||
Purchases of property and equipment
|
(17,841
|
)
|
(18,186
|
)
| ||||
Purchases of intangible assets
|
-
|
(1,025
|
)
| |||||
Proceeds from sale of property and equipment
|
146
|
20
| ||||||
Proceeds from sale of clinics
|
77
|
248
| ||||||
Net cash used in investing activities
|
(17,618
|
)
|
(18,943
|
)
| ||||
Financing activities:
| ||||||||
Proceeds from long-term debt
|
500,000
|
-
| ||||||
Deferred financing costs
|
(12,952
|
)
|
-
| |||||
Original issue discount
|
(10,000
|
)
|
-
| |||||
Principal payments on long-term debt
|
(555,048
|
)
|
(452,117
|
)
| ||||
Proceeds from issuance of Series A Senior Preferred Stock
|
144,667
|
- | ||||||
Proceeds from issuance of 2022 Warrants
|
20,333
|
-
| ||||||
Cash inflow from Business Combination
|
-
|
229,338
| ||||||
Payments to Series A Preferred stockholders
|
-
|
(59,000
| ) | |||||
Proceeds from shares issued through PIPE investment
|
-
|
300,000
| ||||||
Equity issuance costs and original issue discount
|
(4,935
|
)
|
(19,233
| ) | ||||
Taxes paid on behalf of employees for shares withheld
|
(34
|
)
|
-
| |||||
Distribution to non-controlling interest holders
|
(612
|
)
|
(4,495
| ) | ||||
Net cash provided by (used in) financing activities
|
81,419
|
(5,507
| ) | |||||
Changes in cash and cash equivalents:
| ||||||||
Net increase (decrease) in cash and cash equivalents
|
31,064
|
(51,559
| ) | |||||
Cash and cash equivalents at beginning of period
|
48,616
|
142,128
| ||||||
Cash and cash equivalents at end of period
|
$
|
79,680
|
$
|
90,569
| ||||
Supplemental noncash disclosures:
| ||||||||
Derivative changes in fair value
|
$
|
(6,460
|
)
|
$
|
(1,197
| ) | ||
Purchases of property and equipment in accounts payable
|
$
|
1,550
|
$
|
1,174
| ||||
Warrant liability recognized upon the closing of the Business Combination
|
$
|
-
|
$
|
(26,936
| ) | |||
Contingent common shares liability recognized upon the closing of the Business Combination
|
$
|
-
|
$
|
(220,500
| ) | |||
Shares issued to Wilco Holdco Series A Preferred stockholders
|
$
|
-
|
$
|
128,453
| ||||
Other supplemental disclosures:
| ||||||||
Cash paid for interest
|
$
|
17,822
|
$
|
28,716
| ||||
Cash paid for taxes
|
$
|
55
|
$
|
30
|
Financial Metrics ($ in 000's)
| |||||||||||||||||||||
Net Patient
Revenue
|
Other
Revenue
|
Net Operating
Revenue
|
Adjusted
EBITDA(1) |
Adj EBITDA
margin(1) | |||||||||||||||||
Q1 2019
|
$
|
170,940
|
$
|
16,277
|
$
|
187,217
|
$
|
25,989
|
13.9
|
%
| |||||||||||
Q2 2019
|
$
|
182,757
|
$
|
16,015
|
$
|
198,772
|
$
|
33,342
|
16.8
|
%
| |||||||||||
Q3 2019
|
$
|
179,561
|
$
|
16,624
|
$
|
196,185
|
$
|
29,455
|
15.0
|
%
| |||||||||||
Q4 2019
|
$
|
184,338
|
$
|
18,946
|
$
|
203,284
|
$
|
39,606
|
19.5
|
%
| |||||||||||
Q1 2020
|
$
|
164,939
|
$
|
17,799
|
$
|
182,738
|
$
|
26,487
|
14.5
|
%
| |||||||||||
Q2 2020
|
$
|
95,003
|
$
|
12,751
|
$
|
107,754
|
$
|
1,189
|
1.1
|
%
| |||||||||||
Q3 2020
|
$
|
132,803
|
$
|
15,852
|
$
|
148,655
|
$
|
17,321
|
11.7
|
%
| |||||||||||
Q4 2020
|
$
|
136,840
|
$
|
16,266
|
$
|
153,106
|
$
|
18,622
|
12.2
|
%
| |||||||||||
Q1 2021
|
$
|
132,271
|
$
|
16,791
|
$
|
149,062
|
$
|
5,590
|
3.8
|
%
| |||||||||||
Q2 2021
|
$
|
146,679
|
$
|
17,354
|
$
|
164,033
|
$
|
23,999
|
14.6
|
%
| |||||||||||
Q3 2021
|
$
|
141,855
|
$
|
17,158
|
$
|
159,013
|
$
|
8,539
|
5.4
|
%
| |||||||||||
Q4 2021
|
$
|
140,275
|
$
|
15,488
|
$
|
155,763
|
$
|
1,643
|
1.1
|
%
| |||||||||||
Q1 2022
|
$
|
138,925
|
$
|
14,897
|
$
|
153,822
|
$
|
(4,695
|
)
|
(3.1
|
)%
| ||||||||||
Q2 2022
|
$
|
148,506
|
$
|
14,787
|
$
|
163,293
|
$
|
5,436
|
3.3
|
%
|
(1) |
Excludes CARES Act Provider Relief Funds of $44.3 million in the second quarter of 2020, $23.1 million in the third quarter of 2020, and $24.1 million in the fourth quarter of 2020.
|
Operational Metrics: PT Clinics
| |||||||||||||||||||||||||
Ending
Clinic Count
|
Visits
per Day(1) |
Clinical
FTE(2) |
VPD
per cFTE(3) |
Annualized Clinician
Adds %(4) |
Annualized Clinician
Turnover %(5) | ||||||||||||||||||||
Q1 2019
|
825
|
24,142
|
2,833
|
8.5
|
20
|
%
|
19
|
%
| |||||||||||||||||
Q2 2019
|
836
|
25,527
|
2,862
|
8.9
|
26
|
%
|
21
|
%
| |||||||||||||||||
Q3 2019
|
847
|
25,229
|
2,901
|
8.7
|
37
|
%
|
26
|
%
| |||||||||||||||||
Q4 2019
|
872
|
25,693
|
2,936
|
8.8
|
17
|
%
|
26
|
%
| |||||||||||||||||
Q1 2020
|
868
|
22,855
|
2,841
|
8.0
|
17
|
%
|
22
|
%
| |||||||||||||||||
Q2 2020
|
866
|
12,643
|
1,487
|
8.5
|
0
|
%
|
20
|
%
| |||||||||||||||||
Q3 2020
|
873
|
18,159
|
2,004
|
9.1
|
9
|
%
|
82
|
%
| |||||||||||||||||
Q4 2020
|
875
|
19,441
|
2,214
|
8.8
|
43
|
%
|
34
|
%
| |||||||||||||||||
Q1 2021
|
882
|
19,520
|
2,284
|
8.5
|
44
|
%
|
32
|
%
| |||||||||||||||||
Q2 2021
|
889
|
21,569
|
2,325
|
9.3
|
44
|
%
|
44
|
%
| |||||||||||||||||
Q3 2021
|
900
|
20,674
|
2,359
|
8.8
|
63
|
%
|
41
|
%
| |||||||||||||||||
Q4 2021
|
910
|
20,649
|
2,490
|
8.3
|
44
|
%
|
37
|
%
| |||||||||||||||||
Q1 2022
|
922
|
21,062
|
2,466
|
8.5
|
39
|
%
|
28
|
%
| |||||||||||||||||
Q2 2022
|
926
|
22,403
|
2,465
|
9.1
|
38
|
%
|
37
|
%
|
(1) |
Equals patient visits divided by operating days.
|
(2) |
Represents clinical staff hours divided by 8 hours divided by number of paid days.
|
(3) |
Equals patient visits divided by operating days divided by clinical full-time equivalent employees.
|
(4) |
Represents clinician headcount new hire adds divided by average clinician headcount, multiplied by 4 to annualize.
|
(5) |
Represents clinician headcount separations divided by average clinician headcount, multiplied by 4 to annualize.
|
Unit Economics: PT Clinics ($ actual)
| |||||||||||||||||||||||||
PT Revenue
per Clinic(1) |
VPD
per Clinic(2) |
PT Rate
per Visit(3) |
PT Salaries
per Visit(4) |
PT Rent
and Other
per Clinic(5) |
PT Provision
as % PT Revenue(6) | ||||||||||||||||||||
Q1 2019
|
$
|
208,803
|
29.5
|
$
|
112.39
|
$
|
57.21
|
$
|
48,682
|
4.3
|
%
| ||||||||||||||
Q2 2019
|
$
|
219,748
|
30.7
|
$
|
111.87
|
$
|
55.21
|
$
|
48,130
|
3.2
|
%
| ||||||||||||||
Q3 2019
|
$
|
213,255
|
30.0
|
$
|
111.21
|
$
|
56.47
|
$
|
48,995
|
2.8
|
%
| ||||||||||||||
Q4 2019
|
$
|
213,767
|
29.8
|
$
|
112.10
|
$
|
54.65
|
$
|
47,843
|
2.1
|
%
| ||||||||||||||
Q1 2020
|
$
|
189,658
|
26.3
|
$
|
112.76
|
$
|
55.11
|
$
|
50,258
|
3.6
|
%
| ||||||||||||||
Q2 2020
|
$
|
109,872
|
14.6
|
$
|
117.41
|
$
|
53.39
|
$
|
43,621
|
4.1
|
%
| ||||||||||||||
Q3 2020
|
$
|
152,472
|
20.8
|
$
|
112.51
|
$
|
53.83
|
$
|
44,140
|
2.2
|
%
| ||||||||||||||
Q4 2020
|
$
|
155,913
|
22.2
|
$
|
109.98
|
$
|
52.16
|
$
|
47,168
|
2.4
|
%
| ||||||||||||||
Q1 2021
|
$
|
150,536
|
22.2
|
$
|
107.56
|
$
|
54.14
|
$
|
47,722
|
5.4
|
%
| ||||||||||||||
Q2 2021
|
$
|
165,241
|
24.3
|
$
|
106.26
|
$
|
48.22
|
$
|
47,857
|
2.4
|
%
| ||||||||||||||
Q3 2021
|
$
|
158,556
|
23.1
|
$
|
105.56
|
$
|
53.70
|
$
|
49,499
|
2.5
|
%
| ||||||||||||||
Q4 2021
|
$
|
154,772
|
22.8
|
$
|
104.51
|
$
|
55.73
|
$
|
50,976
|
1.5
|
%
| ||||||||||||||
Q1 2022
|
$
|
151,225
|
22.9
|
$
|
103.06
|
$
|
55.47
|
$
|
54,472
|
3.7
|
%
| ||||||||||||||
Q2 2022
|
$
|
160,431
|
24.2
|
$
|
103.57
|
$
|
53.64
|
$
|
53,017
|
2.4
|
%
|
(1) |
Equals Net Patient Revenue divided by average clinics over the quarter.
|
(2) |
Equals patient visits divided by operating days divided by average clinics over the quarter
|
(3) |
Equals Net Patient Revenue divided by patient visits.
|
(4) |
Equals estimated patient-related portion of Salaries and Related Costs divided by patient visits.
|
(5) |
Equals estimated patient-related portion of Rent, Clinic Supplies, Contract Labor and Other divided by average clinics over the quarter.
|
(6) |
Equals estimated patient-related portion of Provision for Doubtful Accounts divided by Net Patient Revenue.
|
Customer Satisfaction Metrics
| |||||||||
Net Promoter
Score(1) |
Google Star
Rating(2) | ||||||||
Q1 2019
|
77
|
4.6
| |||||||
Q2 2019
|
79
|
4.9
| |||||||
Q3 2019
|
78
|
4.9
| |||||||
Q4 2019
|
79
|
4.8
| |||||||
Q1 2020
|
77
|
4.9
| |||||||
Q2 2020
|
77
|
4.9
| |||||||
Q3 2020
|
78
|
4.6
| |||||||
Q4 2020
|
76
|
4.7
| |||||||
Q1 2021
|
75
|
4.9
| |||||||
Q2 2021
|
77
|
4.9
| |||||||
Q3 2021
|
73
|
4.9
| |||||||
Q4 2021
|
78
|
4.8
| |||||||
Q1 2022
|
74
|
4.9
| |||||||
Q2 2022
|
75
|
4.9
|
(1) |
NPS measures customer experience from ATI patient survey responses. The score is calculated as the percentage of promoters less the percentage of detractors.
|
(2) |
A Google Star rating is a five-star rating scale that ranks businesses based on customer reviews. Customers are given the opportunity to leave a business review after interacting with a business, which involves choosing from one star (poor) to five stars (excellent).
|
Three Months Ended
| ||||||||
June 30, 2022
|
March 31, 2022
| |||||||
Net loss
|
$
|
(135,723
|
)
|
$
|
(138,223
|
)
| ||
Plus (minus):
| ||||||||
Net loss attributable to non-controlling interests
|
177
|
473
| ||||||
Interest expense, net
|
11,379
|
8,656
| ||||||
Income tax benefit
|
(13,033
|
)
|
(23,281
|
)
| ||||
Depreciation and amortization expense
|
10,055
|
9,900
| ||||||
EBITDA
|
$
|
(127,145
|
)
|
$
|
(142,475
|
)
| ||
Goodwill and intangible asset impairment charges(1) |
127,820
|
155,741
| ||||||
Goodwill and intangible asset impairment charges attributable to non-controlling interests(1) |
(654
|
)
|
(940
|
)
| ||||
Changes in fair value of warrant liability and contingent common shares liability(2) |
(2,680
|
)
|
(26,011
|
)
| ||||
Loss on debt extinguishment(3) |
-
|
2,809
| ||||||
Loss on legal settlement(4) |
3,000
|
-
| ||||||
Non-ordinary legal and regulatory matters(5) |
2,202
|
2,497
| ||||||
Share-based compensation
|
2,004
|
1,964
| ||||||
Transaction and integration costs(6) |
603
|
1,538
| ||||||
Pre-opening de novo costs(7) |
286
|
381
| ||||||
Gain on sale of Home Health service line, net
|
-
|
(199
|
)
| |||||
Adjusted EBITDA
|
$
|
5,436
|
$
|
(4,695
|
)
|
(1) |
Represents non-cash charges related to the write-down of goodwill and trade name indefinite-lived intangible assets.
|
(2) |
Represents non-cash amounts related to the change in the estimated fair value of IPO Warrants, Earnout Shares and Vesting Shares.
|
(3) |
Represents charges related to the derecognition of the unamortized deferred financing costs and original issuance discount associated with the full repayment of the 2016 first lien term loan.
|
(4) |
Represents estimated charge for probable net settlement liability related to billing dispute.
|
(5) |
Represents non-ordinary course legal costs related to the previously-disclosed ATIP shareholder class action complaints, derivative complaint and SEC inquiry.
|
(6) |
Represents costs related to the Business Combination with FVAC II and non-capitalizable debt transaction costs.
|
(7) |
Represents expenses associated with renovation, equipment and marketing costs relating to the start-up and launch of new locations incurred prior to opening.
|
Three Months Ended
| ||||||||||||||||
December 31,
|
September 30,
|
June 30,
|
March 31,
| |||||||||||||
2021
|
2021
|
2021
|
2021
| |||||||||||||
Net income (loss)
|
$
|
1,690
|
$
|
(326,774
|
)
|
$
|
(439,126
|
)
|
$
|
(17,818
|
)
| |||||
Plus (minus):
| ||||||||||||||||
Net (income) loss attributable to non-controlling interests
|
(869
|
)
|
2,109
|
3,769
|
(1,309
|
)
| ||||||||||
Interest expense, net
|
7,215
|
7,386
|
15,632
|
16,087
| ||||||||||||
Interest expense on redeemable preferred stock
|
-
|
-
|
4,779
|
5,308
| ||||||||||||
Income tax benefit
|
(5,381
|
)
|
(35,333
|
)
|
(19,731
|
)
|
(10,515
|
)
| ||||||||
Depreciation and amortization expense
|
10,005
|
9,222
|
9,149
|
9,619
| ||||||||||||
EBITDA
|
12,660
|
(343,390
|
)
|
(425,528
|
)
|
1,372
| ||||||||||
Goodwill and intangible asset impairment charges(1) |
-
|
508,972
|
453,331
|
-
| ||||||||||||
Goodwill and intangible asset impairment charges attributable to non-controlling interest(1) |
-
|
(2,928
|
)
|
(5,021
|
)
|
-
| ||||||||||
Changes in fair value of warrant liability and contingent common shares liability(2) |
(10,046
|
)
|
(162,202
|
)
|
(25,487
|
)
|
-
| |||||||||
Gain on sale of Home Health service line, net
|
(5,846
|
)
|
-
|
-
|
-
| |||||||||||
Reorganization and severance costs(3) |
-
|
3,551
|
-
|
362
| ||||||||||||
Transaction and integration costs(4) |
955
|
2,335
|
3,580
|
2,918
| ||||||||||||
Share-based compensation
|
905
|
1,248
|
3,112
|
504
| ||||||||||||
Pre-opening de novo costs(5) |
543
|
511
|
441
|
434
| ||||||||||||
Non-ordinary legal and regulatory matters(6) |
2,472
|
442
|
-
|
-
| ||||||||||||
Loss on debt extinguishment(7) |
-
|
-
|
5,534
|
-
| ||||||||||||
Loss on settlement of redeemable preferred stock(8) |
-
|
-
|
14,037
|
-
| ||||||||||||
Adjusted EBITDA
|
$
|
1,643
|
$
|
8,539
|
$
|
23,999
|
$
|
5,590
|
(1) |
Represents non-cash charges related to the write-down of goodwill and trade name indefinite-lived intangible assets.
|
(2) |
Represents non-cash amounts related to the change in the estimated fair value of Warrants, Earnout Shares and Vesting Shares.
|
(3) |
Represents severance, consulting and other costs related to discrete initiatives focused on reorganization and delayering of the Company's labor model, management structure and support functions.
|
(4) |
Represents costs related to the Company's business combination with FVAC II, non-capitalizable debt transaction costs, clinic acquisitions and acquisition-related integration and consulting and planning costs related to preparation to operate as a public company.
|
(5) |
Represents expenses associated with renovation, equipment and marketing costs relating to the start-up and launch of new locations incurred prior to opening.
|
(6) |
Represents non-ordinary course legal costs related to the previously-disclosed ATIP shareholder class action complaints, derivative complaint and SEC inquiry.
|
(7) |
Represents charges related to the derecognition of the proportionate amount of remaining unamortized deferred financing costs and original issuance discount associated with the partial repayment of the first lien term loan and derecognition of the unamortized original issuance discount associated with the full repayment of the subordinated second lien term loan.
|
(8) |
Represents loss on settlement of redeemable preferred stock based on the value of cash and equity provided to preferred stockholders in relation to the outstanding redeemable preferred stock liability at the time of the closing of the business combination with FVAC II.
|
Three Months Ended
| ||||||||||||||||
December 31,
|
September 30,
|
June 30,
|
March 31,
| |||||||||||||
2020
|
2020
|
2020
|
2020
| |||||||||||||
Net income (loss)
|
$
|
2,190
|
$
|
1,022
|
$
|
4,596
|
$
|
(8,106
|
)
| |||||||
Plus (minus):
| ||||||||||||||||
Net income attributable to non-controlling interests
|
(987
|
)
|
(901
|
)
|
(1,855
|
)
|
(1,330
|
)
| ||||||||
Interest expense, net
|
16,404
|
17,346
|
17,683
|
17,858
| ||||||||||||
Interest expense on redeemable preferred stock
|
5,154
|
4,896
|
4,604
|
4,377
| ||||||||||||
Income tax (benefit) expense
|
(2,033
|
)
|
2,322
|
3,568
|
(1,792
|
)
| ||||||||||
Depreciation and amortization expense
|
10,072
|
9,880
|
9,763
|
9,985
| ||||||||||||
EBITDA
|
30,800
|
34,565
|
38,359
|
20,992
| ||||||||||||
Reorganization and severance costs(1) |
679
|
4,436
|
1,255
|
1,142
| ||||||||||||
Transaction and integration costs(2) |
3,747
|
75
|
100
|
868
| ||||||||||||
Share-based compensation
|
503
|
473
|
466
|
494
| ||||||||||||
Pre-opening de novo costs(3) |
335
|
368
|
268
|
594
| ||||||||||||
Business optimization costs(4) |
2,450
|
519
|
5,011
|
2,397
| ||||||||||||
Charges related to lease terminations(5) |
4,253
|
-
|
-
|
-
| ||||||||||||
Adjusted EBITDA
|
$
|
42,767
|
$
|
40,436
|
$
|
45,459
|
$
|
26,487
|
(1) |
Represents severance, consulting and other costs related to discrete initiatives focused on reorganization and delayering of the Company's labor model, management structure and support functions.
|
(2) |
Represents costs related to the Company's business combination with FVAC II, clinic acquisitions and acquisition-related integration and consulting and planning costs related to preparation to operate as a public company.
|
(3) |
Represents expenses associated with renovation, equipment and marketing costs relating to the start-up and launch of new locations incurred prior to opening.
|
(4) |
Represents non-recurring costs to optimize our platform and ATI transformative initiatives. Costs primarily relate to duplicate costs driven by IT and Revenue Cycle Management conversions, labor related costs during the transition of key positions and other incremental costs of driving optimization initiatives.
|
(5) |
Represents charges related to lease terminations prior to the end of term for corporate facilities no longer in use.
|
Three Months Ended
| ||||||||||||||||
December 31,
|
September 30,
|
June 30,
|
March 31,
| |||||||||||||
2019
|
2019
|
2019
|
2019
| |||||||||||||
Net income (loss)
|
$
|
31,914
|
$
|
(6,046
|
)
|
$
|
(4,816
|
)
|
$
|
(11,303
|
)
| |||||
Plus (minus):
| ||||||||||||||||
Net income attributable to non-controlling interests
|
(1,234
|
)
|
(878
|
)
|
(933
|
)
|
(1,355
|
)
| ||||||||
Interest expense, net
|
18,022
|
19,263
|
19,927
|
19,760
| ||||||||||||
Interest expense on redeemable preferred stock
|
4,206
|
4,000
|
3,763
|
3,542
| ||||||||||||
Income tax benefit
|
(36,095
|
)
|
(2,055
|
)
|
(1,825
|
)
|
(4,044
|
)
| ||||||||
Depreciation and amortization expense
|
9,884
|
9,567
|
9,635
|
10,018
| ||||||||||||
EBITDA
|
26,697
|
23,851
|
25,751
|
16,618
| ||||||||||||
Reorganization and severance costs(1) |
3,401
|
120
|
775
|
4,035
| ||||||||||||
Transaction and integration costs(2) |
3,998
|
198
|
310
|
29
| ||||||||||||
Share-based compensation
|
(57
|
)
|
559
|
795
|
525
| |||||||||||
Pre-opening de novo costs(3) |
438
|
757
|
487
|
593
| ||||||||||||
Business optimization costs(4) |
5,129
|
3,970
|
5,224
|
4,189
| ||||||||||||
Adjusted EBITDA
|
$
|
39,606
|
$
|
29,455
|
$
|
33,342
|
$
|
25,989
|
(1) |
Represents severance, consulting and other costs related to discrete initiatives focused on reorganization and delayering of the Company's labor model, management structure and support functions.
|
(2) |
Represents costs related to the Company's business combination with FVAC II, clinic acquisitions and acquisition-related integration and consulting and planning costs related to preparation to operate as a public company.
|
(3) |
Represents expenses associated with renovation, equipment and marketing costs relating to the start-up and launch of new locations incurred prior to opening.
|
(4) |
Represents non-recurring costs to optimize our platform and ATI transformative initiatives. Costs primarily relate to duplicate costs driven by IT and Revenue Cycle Management conversions, labor related costs during the transition of key positions and other incremental costs of driving optimization initiatives.
|
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
ATI Physical Therapy Inc. published this content on 08 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 August 2022 22:14:33 UTC.